MedTrace Logo

Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer

NCT02618356 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2017-10-02

No results posted yet for this study

Summary

The primary endpoint is to evaluate the Median disease progression free survival (mPFS).

Conditions

Interventions

DRUG

Raltitrexed and S-1

Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle. BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d * 1.25m2 - \<1.5 m2 100 mg/d * 1.5 m2 120 mg/d

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Wei Jian Guo, doctor · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-25
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618356 on ClinicalTrials.gov